Reversible contraception: Clinical sciences

Last updated: January 30, 2025

Reversible contraception: Clinical sciences

obs and gyn

obs and gyn

Anatomy of the pelvic girdle
Anatomy of the pelvic cavity
Anatomy of the breast
Arteries and veins of the pelvis
Nerves and lymphatics of the pelvis
Anatomy of the female urogenital triangle
Anatomy of the perineum
Anatomy of the female reproductive organs of the pelvis
Anatomy clinical correlates: Breast
Anatomy clinical correlates: Female pelvis and perineum
Development of the reproductive system
Mammary gland histology
Ovary histology
Fallopian tube and uterus histology
Cervix and vagina histology
Anatomy and physiology of the female reproductive system
Puberty and Tanner staging
Estrogen and progesterone
Menstrual cycle
Menopause
Pregnancy
Oxytocin and prolactin
Stages of labor
Breastfeeding
Precocious puberty
Delayed puberty
Klinefelter syndrome
Turner syndrome
Androgen insensitivity syndrome
5-alpha-reductase deficiency
Kallmann syndrome
Amenorrhea
Ovarian cyst
Premature ovarian failure
Polycystic ovary syndrome
Ovarian torsion
Krukenberg tumor
Ovarian sex-cord stromal tumors
Ovarian surface epithelial tumors
Ovarian germ cell tumors
Uterine fibroid
Endometriosis
Endometritis
Endometrial hyperplasia
Endometrial cancer
Choriocarcinoma
Cervical cancer
Pelvic inflammatory disease
Urethritis
Female sexual interest and arousal disorder
Orgasmic dysfunction
Genito-pelvic pain and penetration disorder
Mastitis
Fibrocystic breast changes
Intraductal papilloma
Phyllodes tumor
Paget disease of the breast
Breast cancer
Hyperemesis gravidarum
Gestational hypertension
Preeclampsia & eclampsia
Gestational diabetes
Cervical incompetence
Placenta previa
Placenta accreta
Placental abruption
Oligohydramnios
Polyhydramnios
Potter sequence
Intrauterine growth restriction
Preterm labor
Postpartum hemorrhage
Chorioamnionitis
Congenital toxoplasmosis
Congenital cytomegalovirus (NORD)
Congenital syphilis
Neonatal conjunctivitis
Neonatal herpes simplex
Congenital rubella syndrome
Neonatal sepsis
Neonatal meningitis
Miscarriage
Gestational trophoblastic disease
Ectopic pregnancy
Fetal hydantoin syndrome
Fetal alcohol syndrome
Disorders of sex chromosomes: Pathology review
Prostate disorders and cancer: Pathology review
Testicular tumors: Pathology review
Uterine disorders: Pathology review
Ovarian cysts and tumors: Pathology review
Cervical cancer: Pathology review
Vaginal and vulvar disorders: Pathology review
Benign breast conditions: Pathology review
Breast cancer: Pathology review
Complications during pregnancy: Pathology review
Congenital TORCH infections: Pathology review
Disorders of sexual development and sex hormones: Pathology review
Amenorrhea: Pathology review
Testicular and scrotal conditions: Pathology review
Sexually transmitted infections: Warts and ulcers: Pathology review
Sexually transmitted infections: Vaginitis and cervicitis: Pathology review
HIV and AIDS: Pathology review
Estrogens and antiestrogens
Progestins and antiprogestins
Androgens and antiandrogens
Aromatase inhibitors
Uterine stimulants and relaxants
Routine prenatal care: Clinical
Hypertensive disorders of pregnancy: Clinical
Antepartum hemorrhage: Clinical
Premature rupture of membranes: Clinical
Abnormal labor: Clinical
Vaginal versus cesarean delivery: Clinical
Postpartum hemorrhage: Clinical
Gestational trophoblastic disease: Clinical
Abdominal pain: Clinical
Amenorrhea: Clinical
Contraception: Clinical
Virilization: Clinical
Infertility: Clinical
Vulvovaginitis: Clinical
Sexually transmitted infections: Clinical
Abnormal uterine bleeding: Clinical
Ovarian cysts, cancer, and other adnexal masses: Clinical
Endometrial hyperplasia and cancer: Clinical
Cervical cancer: Clinical
Vaginal cancer: Clinical
Vulvar cancer: Clinical
Urinary incontinence: Pathology review
Preconception care: Clinical sciences
Antepartum care (first trimester): Clinical sciences
Antepartum care (second trimester): Clinical sciences
Antepartum care (third trimester): Clinical sciences
Fetal aneuploidy screening: Clinical sciences
Induction of labor: Clinical sciences
Pain management during labor: Clinical sciences
Approach to acute pelvic pain (GYN): Clinical sciences
Ectopic pregnancy: Clinical sciences
Early pregnancy loss: Clinical sciences
Anemia in pregnancy: Clinical sciences
Hemoglobinopathies in pregnancy: Clinical sciences
Approach to diabetes in pregnancy: Clinical sciences
Diabetes in pregnancy (GDM, T1DM, and T2DM): Clinical sciences
Group B streptococcus (GBS) colonization in pregnancy: Clinical sciences
Intraamniotic infection: Clinical sciences
Alcohol, tobacco, cannabinoid, and substance use in pregnancy: Clinical sciences
Asthma in pregnancy: Clinical sciences
Cholestasis of pregnancy: Clinical sciences
Nausea and vomiting of pregnancy: Clinical sciences
Approach to hypertensive disorders in pregnancy: Clinical sciences
Gestational hypertension, preeclampsia, eclampsia, and HELLP: Clinical sciences
Protraction and arrest disorders: Clinical sciences
Placenta previa and vasa previa: Clinical sciences
Placental abruption: Clinical sciences
Breast abscess: Clinical sciences
Mastitis: Clinical sciences
Approach to postpartum hemorrhage: Clinical sciences
Placenta accreta spectrum: Clinical sciences
Uterine atony: Clinical sciences
Late-term and postterm pregnancy: Clinical sciences
Well-patient care (GYN): Clinical sciences
Cervical cancer screening: Clinical sciences
Sexually transmitted infection screening (GYN): Clinical sciences
Emergency contraception: Clinical sciences
Permanent contraception (sterilization): Clinical sciences
Reversible contraception: Clinical sciences
Approach to vaginal discharge: Clinical sciences
Bacterial vaginosis: Clinical sciences
Chlamydia trachomatis infection: Clinical sciences
Neisseria gonorrhoeae infection: Clinical sciences
Pelvic inflammatory disease: Clinical sciences
Vaginal trichomoniasis: Clinical sciences
Vulvovaginal candidiasis: Clinical sciences
Approach to dysuria: Clinical sciences
Hepatitis B: Clinical sciences
Catheter-associated urinary tract infection: Clinical sciences
Lower urinary tract infection: Clinical sciences
Pyelonephritis: Clinical sciences
Approach to urinary incontinence (GYN): Clinical sciences
Adnexal torsion: Clinical sciences
Adenomyosis: Clinical sciences
Uterine leiomyoma: Clinical sciences
Approach to primary amenorrhea: Clinical sciences
Polycystic ovary syndrome (PCOS): Clinical sciences
Approach to postmenopausal bleeding: Clinical sciences
Primary dysmenorrhea: Clinical sciences
Approach to adnexal masses: Clinical sciences
Development of the fetal membranes
Development of the placenta
Development of the umbilical cord
Fetal circulation
Development of twins
Mood disorders: Pathology review
Urinary tract infections: Pathology review
Newborn management: Clinical
Mood disorders: Clinical
Perinatal infections: Clinical
Urinary tract infections: Clinical
Breast cancer: Clinical
Precocious and delayed puberty: Clinical
Congenital adrenal hyperplasia: Clinical

Decision-Making Tree

Transcript

Watch video only

Reversible contraception refers to any method of pregnancy prevention that doesn’t impact future fertility. Options for reversible contraception include hormonal birth control pills, patches, vaginal rings, and injections; long-acting-reversible-contraceptives, or LARC’s, such as implants and IUDs; and non-hormonal, non-LARC options like spermicides, fertility awareness, withdrawal and barrier methods. All individuals who desire contraception should be offered comprehensive counseling, with a focus on their values, preferences, and lived experiences. Shared decision-making is recommended when providing care to help individuals achieve their reproductive goals.

When a patient presents for reversible contraception, start with a focused history and physical exam. First, assess your patient’s preference and provide patient-centered contraceptive counseling. Be sure to incorporate a reproductive justice framework, which is focused on the understanding that all people have a fundamental right to bodily autonomy, to have or not have children, and to parent their children in safe and sustainable communities. Part of acknowledging this framework is awareness of the systemic and structural barriers that people of different descent, low incomes, mental illness, and incarceration have been subject to throughout history. Specifically, marginalized groups have undergone contraceptive experimentation without informed consent, government-sponsored forced sterilization, and other mistreatment.

As such, counseling should be viewed as an opportunity to review your patient's individual values, preferences, and lived experiences, in an open and safe environment. Additionally, take time to reflect and recognize any of your own unconscious or explicit biases that may influence the efficacy of your counseling. Finally, be sure to incorporate shared decision-making into your practice.

Next, assess your patient's medical eligibility criteria, or MEC, for each contraceptive method. The MEC is a set of standards that provides recommendations on the safety of contraceptives in the setting of different medical conditions.

During your history, assess the patient’s age and first day of their last menstrual period. Review their sexual history and 5 Ps, or partners, practices, past history of sexually transmitted infections, or STIs, prevention of STIs, and prevention of pregnancy. While this information is not absolutely required for contraception, it can help guide conversations on safe sexual practices and provide informed counseling.

Next, review medical conditions that are contraindicated for systemic hormonal contraception, including migraines with aura, hypertension, tobacco use, breast cancer, undiagnosed abnormal uterine bleeding, and acute liver disease.

Following this, assess for mental health conditions, specifically mood disorders like depression or bipolar disorder, as some patients may have worsening of symptoms with hormonal contraceptives. Also evaluate for mental or physical disabilities, which may limit a patient’s ability to reliably use contraceptives or tolerate placement of a LARC.

Additionally, review the patient's breastfeeding and postpartum status, as this will limit contraceptive options. Finally, review all medications, because certain anti-epileptic drugs, antibiotics, and antiretrovirals can reduce the efficacy of combined oral contraceptive pills, or COCs.

On physical exam, assess blood pressure and BMI. While routine pelvic exam and/or ultrasound is not necessary prior to prescribing contraception, you may opt to perform them if the patient desires an IUD to assess uterine size. If performing a pelvic exam, you can also evaluate for evidence of an active STI. For labs, obtain a pregnancy test and consider STI screening. If history and/or physical exam warrants further work-up, a pelvic ultrasound might be recommended.

Okay, if the pregnancy test is positive… perform individualized counseling. If negative, counsel on all reversible contraceptive options.

Let’s start with patients who desire hormonal, non-LARC, contraception. This includes combined oral contraceptive pills, or COCs, which contain both estrogen and progestin; and progestin-only pills, called POPs. There are also options for a combined estrogen-progestin contraceptive patch or vaginal ring, and a progestin-only injection called depot medroxyprogesterone acetate, or DMPA for short.

COCs work primarily by preventing ovulation, while also thickening cervical mucus making it more difficult for sperm to enter the uterus, and thinning the endometrium. Benefits of COCs include ease of access and use, plus non-contraceptive benefits like regular, lighter, and shorter menses, reduced menstrual cramps, and decreased risk of uterine, ovarian, and colon cancer. The biggest disadvantage is that patients must remember to take their pills at the same time every day!

Risks to COCs and other methods of combined hormonal contraception like the patch and vaginal ring, are rare but include a small increase in venous thromboembolism, or VTE, myocardial infarction, and stroke. This risk is highest in individuals over 35 years old who smoke more than 15 cigarettes a day, or in people with multiple cardiovascular risk factors or a history of migraines with aura.

Also, if your patient is postpartum, refrain from COCs for at least 21 days following delivery due to increased VTE risk, and avoid COCs in breastfeeding individuals as estrogen may affect milk production.

Sources

  1. "Patient-Centered Contraceptive Counseling: ACOG Committee Statement Number 1" Obstet Gynecol (2022)
  2. "Committee Opinion No. 710: Counseling adolescents about contraception" Obstet Gynecol (2017)
  3. "Practice Bulletin No. 186: Long-acting reversible contraception: implants and intrauterine devices" Obstet Gynecol (2017)
  4. "US Medical Eligibility Criteria (US-MEC) for contraceptive use" Centers for Disease Control and Prevention (2016)
  5. "Oral Contraceptive Pills" StatPearls (2022)
  6. "Progestin" StatPearls (2023)